Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: A survey of GPs' awareness and knowledge

A. Munro; J.P. Codde; J.B. Semmens; Yee Leung; K. Spilsbury; V. Williams; N. Steel; Paul Cohen; H. Pavicic; V. Westoby; P.C. O'Leary

Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: A survey of GPs' awareness and knowledge

A. Munro, J.P. Codde, J.B. Semmens, Yee Leung, K. Spilsbury, V. Williams, N. Steel, Paul Cohen, H. Pavicic, V. Westoby, P.C. O'Leary

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Background: Patients have an increased risk of persistent/recurrent cervical disease if they received treatment for a high-grade squamous intraepithelial lesion (HSIL). Consequently, understanding whether co-testing (human papillomavirus [HPV] DNA testing and cervical cytology) is fully utilised by general practitioners (GPs) is paramount. Methods: After consultation with key stakeholders, an anonymous, self-completion questionnaire was developed and disseminated to GPs who had provided cervical cytology. Results: Responses were received from 745 GPs (30.9% response rate). A significant number (34.3%) of GPs were unaware of the use of co-testing (HPV DNA testing and cervical cytology) for the management of patients after HSIL treatment. Additionally, the majority of GPs reported they did not 'always' receive a clear followup plan for patients after treatment of an HSIL. Discussion: GPs require further support and education to ensure successful adoption of co-testing (HPV DNA testing and cervical cytology), specifically, for patients treated for an HSIL.

Original language	English
Pages (from-to)	64-68
Journal	Australian Family Physician
Volume	44
Issue number	1
Publication status	Published - 2015

Cite this

Munro, A. ; Codde, J.P. ; Semmens, J.B. ; Leung, Yee ; Spilsbury, K. ; Williams, V. ; Steel, N. ; Cohen, Paul ; Pavicic, H. ; Westoby, V. ; O'Leary, P.C. / Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: A survey of GPs' awareness and knowledge. In: Australian Family Physician. 2015 ; Vol. 44, No. 1. pp. 64-68.

@article{82016912431f417fbb255a7daab57b94,

title = "Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: A survey of GPs' awareness and knowledge",

abstract = "Background: Patients have an increased risk of persistent/recurrent cervical disease if they received treatment for a high-grade squamous intraepithelial lesion (HSIL). Consequently, understanding whether co-testing (human papillomavirus [HPV] DNA testing and cervical cytology) is fully utilised by general practitioners (GPs) is paramount. Methods: After consultation with key stakeholders, an anonymous, self-completion questionnaire was developed and disseminated to GPs who had provided cervical cytology. Results: Responses were received from 745 GPs (30.9% response rate). A significant number (34.3%) of GPs were unaware of the use of co-testing (HPV DNA testing and cervical cytology) for the management of patients after HSIL treatment. Additionally, the majority of GPs reported they did not 'always' receive a clear followup plan for patients after treatment of an HSIL. Discussion: GPs require further support and education to ensure successful adoption of co-testing (HPV DNA testing and cervical cytology), specifically, for patients treated for an HSIL.",

author = "A. Munro and J.P. Codde and J.B. Semmens and Yee Leung and K. Spilsbury and V. Williams and N. Steel and Paul Cohen and H. Pavicic and V. Westoby and P.C. O'Leary",

year = "2015",

language = "English",

volume = "44",

pages = "64--68",

journal = "Australian Family Physician.",

issn = "0300-8495",

publisher = "The Royal Australian College of General Practitioners",

number = "1",

}

Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: A survey of GPs' awareness and knowledge. / Munro, A.; Codde, J.P.; Semmens, J.B.; Leung, Yee; Spilsbury, K.; Williams, V.; Steel, N.; Cohen, Paul; Pavicic, H.; Westoby, V.; O'Leary, P.C.

In: Australian Family Physician, Vol. 44, No. 1, 2015, p. 64-68.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: A survey of GPs' awareness and knowledge

AU - Munro, A.

AU - Codde, J.P.

AU - Semmens, J.B.

AU - Leung, Yee

AU - Spilsbury, K.

AU - Williams, V.

AU - Steel, N.

AU - Cohen, Paul

AU - Pavicic, H.

AU - Westoby, V.

AU - O'Leary, P.C.

PY - 2015

Y1 - 2015

N2 - Background: Patients have an increased risk of persistent/recurrent cervical disease if they received treatment for a high-grade squamous intraepithelial lesion (HSIL). Consequently, understanding whether co-testing (human papillomavirus [HPV] DNA testing and cervical cytology) is fully utilised by general practitioners (GPs) is paramount. Methods: After consultation with key stakeholders, an anonymous, self-completion questionnaire was developed and disseminated to GPs who had provided cervical cytology. Results: Responses were received from 745 GPs (30.9% response rate). A significant number (34.3%) of GPs were unaware of the use of co-testing (HPV DNA testing and cervical cytology) for the management of patients after HSIL treatment. Additionally, the majority of GPs reported they did not 'always' receive a clear followup plan for patients after treatment of an HSIL. Discussion: GPs require further support and education to ensure successful adoption of co-testing (HPV DNA testing and cervical cytology), specifically, for patients treated for an HSIL.

AB - Background: Patients have an increased risk of persistent/recurrent cervical disease if they received treatment for a high-grade squamous intraepithelial lesion (HSIL). Consequently, understanding whether co-testing (human papillomavirus [HPV] DNA testing and cervical cytology) is fully utilised by general practitioners (GPs) is paramount. Methods: After consultation with key stakeholders, an anonymous, self-completion questionnaire was developed and disseminated to GPs who had provided cervical cytology. Results: Responses were received from 745 GPs (30.9% response rate). A significant number (34.3%) of GPs were unaware of the use of co-testing (HPV DNA testing and cervical cytology) for the management of patients after HSIL treatment. Additionally, the majority of GPs reported they did not 'always' receive a clear followup plan for patients after treatment of an HSIL. Discussion: GPs require further support and education to ensure successful adoption of co-testing (HPV DNA testing and cervical cytology), specifically, for patients treated for an HSIL.

M3 - Article

VL - 44

SP - 64

EP - 68

JO - Australian Family Physician.

JF - Australian Family Physician.

SN - 0300-8495

IS - 1

ER -

Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: A survey of GPs' awareness and knowledge

Abstract

Fingerprint

Cite this